ਫੇਫੜਿਆਂ ਦਾ ਕੈਂਸਰ (non-small cell)
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
ਕਿੱਥੇ ਜਾਣਾ ਹੈ
ਭਾਰਤ ਦੀਆਂ 6 ਹਸਪਤਾਲ ਇਸ ਟ੍ਰਾਇਲ ਲਈ ਮਰੀਜ਼ ਲੈ ਰਹੀਆਂ ਹਨ।
ਰਜਿਸਟਰੀ ਸਮਰੀ (ਤਕਨੀਕੀ)
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cancer progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted treatment regimen(s) for participants with known actionable genomic alterations (AGAs). Participants in this study must have cancer that has spread through their body or can't be removed with surgery or treated with definitive radiation. Participa…
Sponsor: Pfizer
NCT07144280 on ClinicalTrials.gov
Last updated on the registry 13 Oct 2026 · read by us 20 Oct 2026